JP2010523534A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523534A5
JP2010523534A5 JP2010501585A JP2010501585A JP2010523534A5 JP 2010523534 A5 JP2010523534 A5 JP 2010523534A5 JP 2010501585 A JP2010501585 A JP 2010501585A JP 2010501585 A JP2010501585 A JP 2010501585A JP 2010523534 A5 JP2010523534 A5 JP 2010523534A5
Authority
JP
Japan
Prior art keywords
compound according
compound
alkyl
haloalkyl
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010501585A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523534A (ja
JP5466145B2 (ja
Filing date
Publication date
Priority claimed from GBGB0706632.7A external-priority patent/GB0706632D0/en
Application filed filed Critical
Publication of JP2010523534A publication Critical patent/JP2010523534A/ja
Publication of JP2010523534A5 publication Critical patent/JP2010523534A5/ja
Application granted granted Critical
Publication of JP5466145B2 publication Critical patent/JP5466145B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010501585A 2007-04-04 2008-04-02 抗増殖性を有する2,6,9−置換プリン誘導体 Expired - Fee Related JP5466145B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US92189707P 2007-04-04 2007-04-04
GBGB0706632.7A GB0706632D0 (en) 2007-04-04 2007-04-04 New purine derivatives
US60/921,897 2007-04-04
GB0706632.7 2007-04-04
PCT/GB2008/001173 WO2008122767A2 (en) 2007-04-04 2008-04-02 2, 6, 9-substituted purine derivatives having anti proliferative properties

Publications (3)

Publication Number Publication Date
JP2010523534A JP2010523534A (ja) 2010-07-15
JP2010523534A5 true JP2010523534A5 (https=) 2011-04-21
JP5466145B2 JP5466145B2 (ja) 2014-04-09

Family

ID=38090893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010501585A Expired - Fee Related JP5466145B2 (ja) 2007-04-04 2008-04-02 抗増殖性を有する2,6,9−置換プリン誘導体

Country Status (13)

Country Link
US (1) US8592581B2 (https=)
EP (1) EP2139893B1 (https=)
JP (1) JP5466145B2 (https=)
CN (1) CN101679434B (https=)
AU (1) AU2008235361B2 (https=)
BR (1) BRPI0809996B8 (https=)
CA (1) CA2681529C (https=)
ES (1) ES2427845T3 (https=)
GB (1) GB0706632D0 (https=)
MX (1) MX2009010660A (https=)
PL (1) PL2139893T3 (https=)
RU (1) RU2461559C2 (https=)
WO (1) WO2008122767A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
GB0903346D0 (en) 2009-02-27 2009-04-08 Cambridge Advanced Tech Transgenic Plants
GB201001075D0 (en) * 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
US9579198B2 (en) 2012-03-01 2017-02-28 Twelve, Inc. Hydraulic delivery systems for prosthetic heart valve devices and associated methods
CA2973949C (en) 2015-01-16 2023-07-11 The General Hospital Corporation Compounds for improving mrna splicing
US11340215B2 (en) 2016-02-26 2022-05-24 Japanese Foundation For Cancer Research Screening method of anticancer agent focused on function of HP1 and evaluation system
KR102524773B1 (ko) * 2017-01-26 2023-04-21 싸이클라셀 리미티드 퓨린 유도체의 제조 방법
EP3388432A1 (en) 2017-04-10 2018-10-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders
CR20210287A (es) 2018-11-01 2022-02-15 Syros Pharmaceuticals Inc Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
RU2754441C2 (ru) * 2019-12-30 2021-09-02 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
GB202000901D0 (en) 2020-01-22 2020-03-04 Cyclacel Ltd Process
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
WO2024105159A1 (en) * 2022-11-16 2024-05-23 University Of Zurich Ligands of the m6a-rna readers
US20240247001A1 (en) 2022-12-16 2024-07-25 Astrazeneca Ab 2,6,9-trisubstituted purines
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
HK1044334A1 (zh) * 1999-02-01 2002-10-18 Cv治疗公司 依赖细胞周期蛋白的激酶2和IκB-α的嘌呤抑制剂
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
DE60205376T2 (de) * 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US6812232B2 (en) * 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US20030229105A1 (en) * 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US20080125404A1 (en) * 2004-08-27 2008-05-29 Cyclacel Limited Purine and Pyrimidine Cdk Inhitbitors and Their use for The Treatment of Autoimmune Diseases
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination

Similar Documents

Publication Publication Date Title
JP2010523534A5 (https=)
RU2009140753A (ru) Соединения
Azzam et al. Efficient synthesis and docking studies of novel benzothiazole-based pyrimidinesulfonamide scaffolds as new antiviral agents and Hsp90α inhibitors
CA2492659A1 (en) 6-(3-pyridyl-methylamino)purine derivatives and their use as antiproliferative agents
JP2007500178A5 (https=)
Holý et al. 6-[2-(Phosphonomethoxy) alkoxy] pyrimidines with antiviral activity
JP5779799B2 (ja) 2’−フルオロ−6’−メチレン炭素環ヌクレオシド類、及びウイルス感染の治療法
US9533990B2 (en) Inhibitors of secretion of hepatitis B virus antigens
US9284298B2 (en) Pyrazolyl-pyrimidine derivatives as kinase inhibitors
CN103827130B (zh) 2′‑氟‑6′‑亚甲基碳环核苷和治疗病毒感染的方法
TWI720250B (zh) 利用tlr7促效劑及hbv蛋白殼組裝抑制劑之組合治療
Sayle et al. Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2
CN118103371A (zh) 一种egfr抑制剂及其制备方法和用途
AU2016202213A1 (en) Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer
JP2007500179A (ja) キナーゼ阻害剤としての2−アミノフェニル−4−フェニルピリミジン
CN111566106B (zh) 作为cdk抑制剂的化合物
CN1353713A (zh) 依赖细胞周期蛋白的激酶2和IκB-α的嘌呤抑制剂
Choi et al. Structure− activity relationships of (e)-5-(2-bromovinyl) uracil and related pyrimidine nucleosides as antiviral agents for herpes viruses
KR20070033962A (ko) 증식성 질병의 치료에서 9h-퓨린-2,6-디아민 유도체의용도 및 신규 9h-퓨린-2,6-디아민 유도체
Dong et al. Discovery of potent and wild-type-sparing fourth-generation EGFR inhibitors for treatment of osimertinib-resistance NSCLC
Romanelli et al. Synthetic approaches to piperazine-containing drugs approved by FDA in the period of 2011–2023
ES2487623T3 (es) Derivados de 6,7,8,9-tetrahidro-pirimido{1,2-a}pirimidin-4-ona, su preparación y su aplicación farmacéutica
De Clercq Dancing with chemical formulae of antivirals: A personal account
US20240101529A1 (en) Antiviral indolinyl compounds and uses thereof
JP2024536858A (ja) Fgfr阻害剤及びその使用方法